1. Targeting T Cell Co-receptors for Cancer Therapy
Margaret K. Callahan, Michael A. Postow, Jedd D. Wolchok 
Immunity 
Volume 44, Issue 5, Pages (May 2016)
DOI: /j.immuni
Copyright © 2016 Elsevier Inc. Terms and Conditions

2. Figure 1
Development of Vitiligo in a Patient with Metastatic Melanoma Responding to Pembrolizumab
Vitiligo has been linked to favorable clinical outcomes in patients with metastatic melanoma treated with PD-1 blockade. In this case, a woman with metastatic melanoma responded to pembrolizumab with a reduction in size of two lesions in the lung (compare A to B and C to D). During treatment, she also developed vitiligo, represented in (E).
Immunity  , DOI: ( /j.immuni )
Copyright © 2016 Elsevier Inc. Terms and Conditions

3. Figure 2
Activity for PD-1-PD-L1 Blocking Agents across Multiple Cancer Types
PD-1- and PD-L1-blocking antibodies have demonstrated activity across a range of cancer types. Abbreviations are as follows: CRC, colorectal cancer; IHC, immunohistochemistry; irRC, immune-related response criteria; ORR, objective response rate; OS, overall survival; and PFS, progression-free survival.
Immunity  , DOI: ( /j.immuni )
Copyright © 2016 Elsevier Inc. Terms and Conditions

4. Figure 3
Comparison of Selected Immune-Related Toxicities in Patients with Metastatic Melanoma Treated with Nivolumab, Ipilimumab, or the Combination of Ipilimumab and Nivolumab
Data were extracted from Larkin et al. (2015b).
Immunity  , DOI: ( /j.immuni )
Copyright © 2016 Elsevier Inc. Terms and Conditions